Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 5;12(3):378.
doi: 10.3390/life12030378.

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story

Viola Cogliati  1 , Serena Capici  1 , Francesca Fulvia Pepe  1 , Pierluigi di Mauro  2 , Francesca Riva  2 , Federica Cicchiello  2 , Claudia Maggioni  2 , Nicoletta Cordani  3 , Maria Grazia Cerrito  3 , Marina Elena Cazzaniga  1   3
Affiliations
Review

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story

Viola Cogliati et al. Life (Basel). .

Abstract

CDK4/6 inhibitors in association with endocrine therapy represent the best therapeutic choice for either endocrine-sensitive or resistant hormone-receptor-positive advanced breast cancer patients. On the contrary, the optimal therapeutic strategy after the failure of CDK4/6 inhibitors-based treatment still remains an open question worldwide. In this review, we analyze the most studied mechanisms of resistance to CDK4/6 inhibitors treatment, as well as the most significant results of retrospective and prospective trials in the setting of progression after CDK4/6 inhibitors, to provide the reader a comprehensive overview from both a preclinical and especially a clinical perspective. In our opinion, an approach based on a deeper knowledge of resistance mechanisms to CDK4/6 inhibitors, but also on a careful analysis of what is done in clinical practice, can lead to a better definition of prospective randomized trials, to implement a personalized sequence approach, based on molecular analyses.

Keywords: CDK4/6 inhibitors; metastatic breast cancer; therapy resistance; treatment sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funder had no role in the study design, collection, analyses or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

References

    1. Yang H., Wang R., Zeng F., Zhao J., Peng S., Ma Y., Chen S., Ding S., Zhong L., Guo W., et al. Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single-center study combined with a large cohort study based on the surveillance, epidemiology and end results database. Oncol. Lett. 2020;20:87. doi: 10.3892/ol.2020.11948. - DOI - PMC - PubMed
    1. Pedersen R.N., Esen B.Ö., Mellemkjær L., Christiansen P., Ejlertsen B., Lash T.L., Nørgaard M., Cronin-Fenton D. The incidence of breast cancer recurrence 10–32 years after primary diagnosis. JNCI J. Natl. Cancer Inst. 2021;Nov 8:djab202. doi: 10.1093/jnci/djab202. - DOI - PMC - PubMed
    1. Cardoso F., Paluch-Shimon S., Senkus E., Curigliano G., Aapro M.S., André F., Barrios C.H., Bergh J., Bhattacharyya G.S., Biganzoli L., et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Ann. Oncol. 2020;31:1623–1649. doi: 10.1016/j.annonc.2020.09.010. - DOI - PMC - PubMed
    1. Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G.S., Hart L., Campone M., Petrakova K., Winer E.P., Janni W., et al. LBA17_PR overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) Ann. Oncol. 2021;32((Suppl. 5)):S1283–S1346.
    1. Portman N., Alexandrou S., Carson E., Wang S., Lim E., Caldon C.E. Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocr.-Relat. Cancer. 2019;26:R15–R30. doi: 10.1530/ERC-18-0317. - DOI - PubMed